Pharmacokinetics, pharmacodynamics, and immunodynamics of daclizumab in a two-dose regimen in liver transplantation

Transplantation

Volumn 73, Issue 10, 2002, Pages 1640-1646

  Koch, Martina ^a   Niemeyer, Gerit ^a   Patel, Indravadan ^a   Light, Susan ^a   Nashan, Bjoern ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CD3 ANTIGEN; CD4 ANTIGEN; CD8 ANTIGEN; CYCLOSPORIN A; CYTOKINE; DRUG ANTIBODY; INTERLEUKIN 15; INTERLEUKIN 2 RECEPTOR; INTERLEUKIN 2 RECEPTOR ANTIBODY; METHYLPREDNISOLONE; PREDNISOLONE; PREDNISONE; STEROID;

ANTIBODY TITER; ARTICLE; ASCITES; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG HALF LIFE; GRAFT REJECTION; HUMAN; HUMAN CELL; LIVER TRANSPLANTATION; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; SIDE EFFECT;

EID: 0037182164     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007890-200205270-00020     Document Type: Article

References (33)

1. Interleukin 2
2. Interleukin-2: Inception, impact and implications
3. The IL-2 receptor complex: Its structure, function, and target genes
4. Randomized controlled trial of a monoclonal antibody against the interleukin-2 receptor (33B3.1) as compared with rabbit antithymocyte globulin for prophylaxis against rejection of renal allografts
5. Early experience with anti-Tac in clinical renal transplantation
6. Anti-IL-2 receptor monoclonal antibody (33B3.1) in prophylaxis of early kidney rejection in humans: A randomized trial versus rabbit antithymocytes globulin
7. Inhibition of alloresponsive naive and memory T cells by CD7 and CD25 antibodies and by cyclosporin
8. Immunoprophylaxis with a monoclonal anti-IL-2 receptor antibody in liver transplant patients
9. A randomized prospective trial of anti-Tac monoclonal antibody in human renal transplantation
10. Prolongation of primate renal allograft survival by anti-Tac, an anti-human IL-2 receptor monoclonal antibody
11. Prevention of rejection of kidney transplants by monoclonal antibody directed against interleukin 2
12. A monoclonal antibody (anti-Tac) reactive with activated and functionally mature human T cells. I. Production of anti-Tac monoclonal antibody and distribution of Tac (+) cells
13. A monoclonal antibody (anti-Tac) reactive with activated and functionally mature human T cells. II. Expression of Tac antigen on activated cytotoxic killer T cells, suppressor cells, and on two types of helper T cells
14. A humanized antibody that binds to the interleukin 2 receptor
15. Anti-Tac-H, a humanized antibody to the interleukin 2 receptor with new features for immunotherapy in malignant and immune disorders
16. Reduced immunogenicity and improved pharmacokinetics of humanized anti-Tac in cynomolgus monkeys
17. Interleukin 2 receptor-target therapy: Rationale and application in organ transplantation
18. Reduction of acute renal allograft rejection by Daclizumab
19. Interleukin-2-receptor blockade with Daclizumab to prevent acute rejection in renal transplantation
20. A phase I trial of humanized anti-interleukin 2 receptor antibody in renal transplantation
21. Outcome of phase III trials and mechanisms of action
22. Randomised trial of basiliximab versus placebo for control of acute cellular rejection in renal allograft recipients
23. Reduction of the occurrence of acute cellular rejection among renal allograft recipients treated with basiliximab, a chimeric anti-interlukin-2-receptor monoclonal antibody
24. Disposition and immunodynamics of basiliximab in liver allograft recipients
25. A population pharmacokinetic screen to identify demographic-clinical covariates of basiliximab in liver transplantation
26. Determination of humanized anti-Tac in human serum by a sandwich enzyme linked immunosorbent assay
27. Analysis of epitopes using a recombinant Cd25 fragment (residues 3-104) as antigen
28. Characterisation of anti-IL-2Rb mAb and definition of three epitopes on the IL-2Rb molecule
29. Screening for basiliximab exposure-response relationship in renal allotransplantation
30. Population pharmacokinetics and exposure-response relationship for basiliximab in kidney transplantation
31. Prolonged action of a chimeric interleukin-2 receptor (CD25) monoclonal antibody used in cadaveric renal transplantation
32. Functional response of T cells blocked by anti-CD25 antibody therapy during cardiac rejection
33. Treatment with the chimeric anti-IL-2Rα basiliximab affects both the IL-2 and IL-15 signaling pathways after clinical kidney transplantation